Back

Notification report


Full notification file


General information

Notification Number
B/NL/19/022

Member State to which the notification was sent
Netherlands

Date of acknowledgement from the Member State Competent Authority
22/01/2020

Title of the Project
A phase II safety, dose finding and feasibility trial of BCART2019.1in
patients with relapsed or resistant B-NHL


Proposed period of release:
01/04/2020 to 31/12/2025

Name of the Institute(s) or Company(ies)
Leiden University Medical Center, Albinusdreef 2
2333 ZA Leiden
PO Box 9600
2300 RC Leiden
The Netherlands;


3. Is the same GMO release planned elsewhere in the Community?
No

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
Other: mammal

Identity of the GMO:
T cells transduced with a replication-deficient lentiviral vector harbouring the chimeric
antigen receptor for targeting CD20 and CD19.


Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
HumanHomoSapiens---

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known